Following positive trial findings , retatrutide, a innovative peptide therapy for treating non-insulin dependent metabolic disorder, has received conditional approval from the Drug and Regulatory Agency ( the Agency ). Early availability is currently expected via specialist weight management centres and particular National Health Service provide… Read More